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Abstract
Background: Inborn errors of metabolism (IEM) represent a subclass of rare inherited diseases caused by a wide
range of defects in metabolic enzymes or their regulation. Of over a thousand characterized IEMs, only about half are
understood at the molecular level, and overall the development of treatment and management strategies has proved
challenging. An overview of the changing landscape of therapeutic approaches is helpful in assessing strategic
patterns in the approach to therapy, but the information is scattered throughout the literature and public data
resources.
Results: We gathered data on therapeutic strategies for 300 diseases into the Drug Database for Inborn Errors of
Metabolism (DDIEM). Therapeutic approaches, including both successful and ineffective treatments, were manually
classified by their mechanisms of action using a new ontology.
Conclusions: We present a manually curated, ontologically formalized knowledgebase of drugs, therapeutic
procedures, and mitigated phenotypes. DDIEM is freely available through a web interface and for download at
http://ddiem.phenomebrowser.net.
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Background
Rare hereditary diseases together make up a significant
component of overall morbidity and mortality around the
world. A disease is considered rare in the United States
(US) if it affects fewer than 200,000 individuals. With
more than 7,000 rare diseases characterized, the overall
population burden is therefore of the order of 20 to 30
million [1]. Consequently, it has become a significant con-
cern for strategic health funding bodies in North America,
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Europe, and elsewhere to coordinate international infras-
tructure, research and development, and delivery of new
therapeutics [2].While much effort has gone into mobiliz-
ing patient data across national boundaries and undertak-
ing extensive genetic studies, the Orphan drug initiatives
in the US starting in 1983, together with ongoing pro-
grams at the FDA and NIH, as well as those funded by
the European Commission and Canadian authorities, saw
a dramatic increase in therapies for rare diseases. These
were notable for a large number of drug repurposing
successes, providing accelerated access to patients [3–5].
Currently, around 15% of new orphan drug approvals
are for metabolic and endocrine therapies, most of these
through the application of small molecules [6].
Metabolic hereditary diseases, or inborn errors of
metabolism (IEMs), are a group of disorders that disrupt
normal metabolism and physiology, ultimately affecting
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almost all biochemical pathways and processes in the
body. Individually metabolic diseases are rare, but, as with
rare disease as a whole, relatively common when consid-
ered as a class of disease [7]. Over 1,000 distinct heredi-
tary metabolic diseases have been identified and recently
assigned to 130 categories in a new nosology [8], although
the underlying causes are only understood for about half
of these diseases.
Data resources have been developed for hereditary
metabolic diseases. For example, the Rare Metabolic
Diseases (RAMEDIS) database [9] contains information
on rare diseases and their treatment options. However,
RAMEDIS covers only 93 different IEMs and primarily
relies on information from case reports and their associ-
ated available data on treatment options for most of the
93 disorders covered. IEMbase is a database that contains
clinical, biochemical, and genetic information on 1,310
IEMs, as well as a nosology that classifies each disease into
one of ten significant categories [10]. However, neither
RAMEDIS nor IEMbase cover different treatment options
and strategies for rare metabolic diseases.
Therapeutic approaches to inherited metabolic diseases
are diverse and have to distinguish, for example, between
loss of function, dominant gain of function, and the gen-
eration of toxic metabolic intermediates. Among thera-
peutic strategies that address metabolic diseases are gene
therapy, metabolite level manipulation, transplantation
or surgery, and small molecule therapies to stabilize or
enhance residual enzyme activity. Therapies may address
the underlying mechanism directly or indirectly. They
may provide symptomatic or prophylactic therapy where
some specific phenotypes of the syndrome are addressed,
and sometimes they improve the long term pathologi-
cal outcomes [11–13]. More importantly, a large number
of rare IEMs do not currently have an approved treat-
ment approach, and new therapeutic strategies are tested
in individual cases or clinical trials, and are subsequently
reported in the scientific literature [14]. An overview
of the strategic landscape of therapeutic approaches to
treating IEMs is of potential use not only for investiga-
tors developing new therapies but also for regulators and
research funders.
We have developed the Drug Database for Inborn
Errors of Metabolism (DDIEM), a database that covers
experimental approaches, clinical treatments (established
as well as investigational therapies) and their outcome,
for diagnosed rare metabolic diseases. Individual dis-
eases are linked to established information resources and
databases. In order to classify therapeutic approaches,
we have created a new ontology of strategies for treat-
ing IEMs and categorized treatments using this ontol-
ogy. The use of an ontology allows for data integration,
aggregation, and query expansion, as well as enhancing
data access according to the FAIR (Findable, Accessible,
Interoperable, Reusable) data principles [15]. We used a
wide variety of public online data sources and, where
possible, we extracted the specific aspects of phenotype
addressed by the therapy from the literature through
manual expert curation. DDIEM is freely available at
http://ddiem.phenomebrowser.net.
Results
DDIEM is a database of therapeutic approaches to treating
IEMs which have been manually extracted from the scien-
tific literature. DDIEM currently covers 300 rare diseases
along with the association of 305 genes and 584 drugs that
were used to treat these diseases; these treatment attempts
have been linked to 1,482 distinct disease-associated phe-
notypes that were influenced by these treatments. The
main entity in DDIEM is the therapeutic procedure which
is used to treat a metabolic disorder; these procedures are
classified based on their underlying mechanism or modal-
ity. We have developed an ontology using the Web Ontol-
ogy Language (OWL) [16] to formalize this classification
of treatments in DDIEM.
Classification of treatment mechanisms: the dDIEM
ontology
There are several existing strategies for classifying treat-
ments for inborn errors of metabolism. Most of these
are concerned with the underlying biochemical error and
affected pathways. For example, ICD-11, based on the
recommendations of the Society for the Study of Inborn
Errors of Metabolism (SSIEM) [17], classifies inborn
errors of metabolism mainly by type of metabolism; e.g.,
lipid metabolism, carbohydrate metabolism. ICD-11 also
has other general axes of classification for IEMs, such as
peroxisomal diseases, and more specific axes of classifica-
tion, such as classifying diseases based on involvement in
purine metabolism. Other nosologies emphasize diagnos-
tic and clinical aspects of disease and, for example, classify
diseases into disorders that either involve only one func-
tional system (such as the immune system) or diseases in
which the basic biochemical lesion affects metabolic path-
ways common to a large number of tissues [17]. The latter
group is divided by molecule type of interest and energy
metabolism. More recently, a nosology of IEM has been
developed which classifies diseases by biochemical entity
and process, a work that emerged from the European
Reference Network for Hereditary Metabolic Disorders
[8]. At least one classification is based neither on bio-
chemical pathway nor clinical manifestation, but rather on
modalities of treatment [12, 18].
While our major interest concerns medical treatment,
we also include dietary modification (i.e., excluding or
augmenting the diet with naturally occurring food sub-
stances). However, most of the available therapeutic
options for IEMs are symptomatic where they treat the
Abdelhakim et al. Orphanet Journal of Rare Diseases          (2020) 15:146 Page 3 of 12
symptoms or downstream effects without addressing the
direct effects of the altered protein underlying the disease.
Some other approaches include Enzyme Replacement
Therapy (ERT) where the missing enzyme is replaced by
infusions of an enzyme that is purified from human or
animal tissue or blood or produced by novel recombinant
techniques [19]. Typically, the enzyme is modified to allow
for a longer half-life, more potent activity, resistance to
degradation or targeting to a specific organ, tissue or cell
type.
Some treatment strategies deliver their effects only if
there is some residual enzymic activity and therefore
their efficacy is dependent on this. Examples are substrate
reduction therapy (SRT) [11], chemical chaperone therapy
[20] and pharmacological chaperone therapy [21]. SRT is
a strategy that works through limiting the amount of sub-
strate synthesized to a level that can be effectively cleared
by the impaired enzyme. The efficacy of SRT is mutation-
specific and dependent on residual enzyme activity level
[22]. Chaperone therapy uses small molecule substances,
often osmolytes. These either facilitate folding or stabilize
misfolded proteins to rescue residual activity, for exam-
ple by reducing abnormal aggregation or interacting with
active sites. [20]. In some cases a disease is amenable to
direct gene therapy [23] which usually alters the somatic
genome to prevent or treat a disease through insertion of
a functional copy of the affected gene [20]. More recently,
the potential for gene editing and epigeneticmodifications
are showing considerable promise [24].
We have developed and implemented theDDIEMontol-
ogy as a framework for classifying treatments by mecha-
nism of action, as described above. This ontology allows
the generation of a well-structured dataset broadly inter-
operable with existing resources. We based the DDIEM
ontology on the Ontology of General Medical Sciences
(OGMS) [25] and havemade it available in the community
ontology repositories BioPortal [26] and AberOWL [27].
In the DDIEM ontology, we classify mechanisms of
treatment using three upper level classes. The first class
covers those treatments that attempt to compensate for
or modulate the biological functions affected by the dys-
functional protein (mechanistically predicated
therapeutic procedure). The second class
covers those that treat symptoms (symptomatic
therapeutic procedure); and the third class
covers surgical or physical procedures such as stem
cell transplantation (surgical or physical
therapeutic procedure). Some therapeutic
strategies combine multiple drugs or other treatment
modalities which work through different mechanisms,
for example one drug addressing the primary lesion and
another its symptomatic consequences. These combina-
tion therapies are also included as a separate class in the
ontology. Figure 1 depicts the structure of the DDIEM
ontology; the definition of each class can be found in
Table 1. Table 2 shows several examples of therapeutic
procedure for the main classes in DDIEM.
The DDIEM ontology is based on an upper-level ontol-
ogy for medical sciences, the OGMS. Reusing such an
upper-level ontology allows us to consistently integrate
the DDIEM ontology with related efforts of formaliz-
ing categories in the biomedical domain, including the
DrugOntology [28] and theMedical ActionOntology [29]
which is currently under development and will broadly
characterize therapeutic procedures.
DDIEM database
In DDIEM, we manually curated over 1,600 scientific lit-
erature articles to record evidence for therapies that have
been attempted for currently 300 rare metabolic diseases;
these 300 metabolic diseases are associated with 305
genes. We classify therapeutic approaches that have been
reported in literature for each disease in DDIEM using
the DDIEM ontology. The distribution of the drugs used
as part of therapeutic procedures and their classification
using the DDIEM ontology is shown in Fig. 2. These ther-
apeutic approaches involve 584 unique drugs and correct
or ameliorate 1,482 distinct phenotypes. For each thera-
peutic strategy, we record both evidence and provenance
information using standardized identifiers and coding sys-
tems. Figure 3 provides an overview of the type of infor-
mation we collect and the relations between the different
types of information.
We identified 30 diseases where the outcomes of a
therapeutic procedure were affected by particular geno-
types or genetic variants. Modifying genotypes may
include genotypes that affect the pharmacological action
of a substance, either positively or negatively. For exam-
ple, in familial hyperinsulinemic hypoglycemia type 3
(OMIM:602485), the Y214C variant in theGCK gene was
found to result in patients’ being unresponsive to diazox-
ide while patients carrying the M197I variant in the same
gene did respond to the treatment [30]. When available,
we record this information in DDIEM.
There are 55 orphan diseases in DDIEM for which we
did not assign any therapeutic strategy class, either due
to absence of information on tested therapeutic interven-
tions in the literature, or the benign status of the disease
which does not usually require any intervention. In the sit-
uation where we were unable to identify any report of a
therapeutic strategy for a disease in DDIEM, we mark the
disease as “no treatment is available”.
Phenotypes in DDIEM that are affected by a thera-
peutic procedure are formally coded using the Human
Phenotype Ontology (HPO) [31] or, if no HPO class could
be identified, using the Mammalian Phenotype Ontol-
ogy (MPO) [32]. In 113 cases we could not identify a
phenotype class matching the described phenotype in
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Fig. 1 Structure of the DDIEM therapeutic ontology. The classes we defined for use in DDIEM are on darker background and consist of subclasses of
Metabolic diseases therapeutic procedure as well as the Combination therapeutic procedure
these two ontologies and recorded the phenotype as free
text; additionally, we requested extension of the HPO
with the missing phenotypes so that we can formally
include them in DDIEM once they become available in
the HPO.
DDIEM includes reviewed reports for a therapeutic
intervention; however, the quality of the evidence for a
reported therapeutic intervention will differ between pub-
lications, ranging from individual case reports to large
clinical trials. In DDIEM, we distinguish between six
different types of evidence provided for the effect of
a therapeutic procedure on disease-associated pheno-
types, and we use the Evidence and Conclusion Ontology
[47] to record evidence for our assertions. We distin-
guish evidence based on animal models (ECO:0000179),
clinical trials ECO:0007121), and experiments on cell
lines (ECO:0001565). In some cases, study authors sug-
gested therapeutic procedures based on clinical observa-
tion alone; we record these as inference by a study author
(ECO:0007764). In rare cases, DDIEM curators inferred
information about a therapeutic procedure although it
was not explicitly stated in the article; we mark this
using the “inferred by curator” evidence (ECO:0000305).
Figure 4 shows the distribution of the evidence codes in
DDIEM. While the evidence codes can provide informa-
tion about the type of study that investigates a therapeutic
intervention, they do not provide quantitative informa-
tion such as sample sizes and statistical measures which
are also required to evaluate the evidence for a therapeu-
tic intervention; in the future, we may extend DDIEM to
also include some quantitative information as part of our
evidence model.
We will continue to extend DDIEM in the future both
in its coverage of diseases as well as by updating infor-
mation on diseases already included in DDIEM. For this
purpose, we plan to search literature for diseases already
included in DDIEM in frequent intervals, and the DDIEM
curators will select and add new information as it becomes
available.
Implementation of fAIR principles
DDIEM is intended as a resource for biomedical and
clinical researchers as well as for computational scien-
tists. To enable DDIEM content to be usable by a wide
range of researchers, we aim to follow the FAIR principles
(Findable, Accessible, Interoperable, and Reusable) [15].
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Table 1 A summary of the main mechanisms of therapeutic procedures for metabolic diseases
Therapeutic procedure Definition
Combination therapeutic procedure A therapeutic procedure using multiple therapies to treat a single
disease. Often all the therapies are pharmaceutical. It can also involve
non-drug therapy, such as the combination of medications, behaviour
modification, or physical procedures. The different components might
act through the same or different mechanisms.
Mechanistically predicated therapeutic procedure A therapeutic procedure which directly addresses the effects of a
protein defect produced by the mutation, its structure, activity, or end
product. Therapies which target the local interaction or regulatory
network or pathway in which the affected protein lies are also regarded
as mechanistic therapies.
Complementation therapy A therapeutic procedure in which a treatment directly or indirectly
compensates for the loss or gain of activity of a genetically defective
protein within the network or pathway of which that protein is a
member.
Direct complementation of a genetically defective protein A therapeutic procedure in which a genetically defective protein is
replaced by a canonical source of the same protein, genetically as in
gene therapy, or by some other means of delivery, whose completion
is hypothesized by a health care provider to eliminate a disorder or to
alleviate the signs and symptoms of a disorder or pathological process.
Compensatory complementation of a genetically defective protein A therapeutic procedure in which the availability, activity, stability, or
turnover of a defective enzyme is modified by delivery of small or
macro-molecules, or genetic or epigenetic manipulation.
Functional complementation of a genetically defective protein A therapeutic procedure in which the composition or metabolic activity
of the pathway or network in which the defective protein is found is
modified, compensating for alteration of activity of that protein.
Dietary regime modification A therapeutic procedure in which the diet is supplemented with or
depleted in molecules closely related to the products or end processes
of a genetically defective protein which occur as natural products in
the diet.
Dietary exclusion A therapeutic procedure in which the diet is depleted in molecules
closely related to the products or end processes of a genetically
defective protein, which occur naturally in the diet.
Dietary supplementation A therapeutic procedure in which the diet is supplemented with
foodstuffs containing molecules closely related to the products or end
processes of a genetically defective protein, which occur naturally in
the diet.
Metabolite replacement A therapeutic procedure involving enteral, parenteral, or transdermal
provision of small molecules closely related to the products or end
processes of a genetically defective protein.
Activity modification of a genetically defective protein A therapeutic procedure in which generally small molecules are
delivered to the organism in order to directly increase, decrease, or
alter the activity or stability of a genetically defective protein.
Symptomatic therapeutic procedure A therapeutic procedure aimed at amelioration of one or more
abnormal phenotypes generated as a consequence of a defective
protein or process by a means unrelated to the immediate pathway or
network environment of the defective protein. Generally working at
the level of the tissue or overall organismal physiology.
Surgical or physical therapeutic procedure A therapeutic procedure to mitigate the immediate or future effects of
the presence of a genetically defective protein which involves physical
conditioning or anatomical modification.
Functional complementation of a genetically defective protein by
inhibition
A therapeutic procedure that inhibits a component of the pathway or
network in which a genetically defective protein is found,
compensating for alteration of activity of that protein.
Functional complementation of a genetically defective protein by
stimulation
A therapeutic procedure that stimulates a component of the pathway
or network in which a genetically defective protein is found,
compensating for alteration of activity of that protein.
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Table 2 Examples of the main mechanisms of therapeutic procedures for metabolic diseases
Therapeutic procedure Examples
Activity modification of a genetically defective protein In Bartter syndrome type 4A (OMIM:602522), tanespimycin
(17-allylamino-17-demethoxygeldanamycin or 17-AAG), an Hsp90 inhibitor,
enhances the plasma membrane expression of mutant barttins (R8L and
G47R) in Madin–Darby canine kidney cells [33].
Activity modification of a genetically defective protein by
epigenetic manipulation
HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with
concomitant changes in the epigenetic state of the gene, in the treatment
of Friedreich’s ataxia (OMIM:229300) [34].
Activity modification of a genetically defective protein by genome
editing
CRISPR-Cas9-mediated gene editing is a potential treatment for Hurler
syndrome (OMIM:607014) as established in cell and animal based studies
[35], [36].
Activity modification of a genetically defective protein by
transcriptional or translational modification
Vitamin D in treating hyperprolinemia (OMIM:239500) and recombinant
human erythropoietin (rhuEPO) in treating Friedreich’s ataxia
(OMIM:229300) are examples of drugs that enhance the activity of
PRODH and FXN respectively by transcriptional modulation of PRODH in
hyperprolinemia and increasing frataxin expression in Friedrich’s ataxia [37]
[38].
Direct complementation of a genetically defective protein Recombinant human IGF1 (mecasermin) is a form of enzyme replacement
therapy in treating insulin-like growth factor I deficiency (OMIM:608747)
[39].
Direct complementation of a genetically defective protein by gene
therapy
An adeno-associated viral vector containing a porphobilinogen deaminase
gene is a treatment for acute intermittent porphyria (OMIM:176000) [40].
Functional complementation of a genetically defective protein by
inhibition
Miglustat is a form of substrate reduction therapy (SRT) used to treat
Gaucher’s disease (OMIM:230800) where miglustat inhibits the
ceramide-specific glucosyltransferase which catalyses the first committed
step of GSL synthesis [41].
Procedure to mitigate dominant effect of a genetically abnormal
protein
In treating hyperinsulinism-hyperammonemia syndrome (OMIM:606762),
diazoxide inhibits insulin release and promotes complete resolution of
hypoglycemia [42].
Dietary exclusion A valine-restricted diet is a treatment for patients suffering from
isobutyryl-CoA dehydrogenase deficiency (OMIM:611283), which inolves
valine metabolism [43].
Dietary supplementation Beneprotein and uncooked cornstarch as high sources of protein and
carbohydrates are used to prevent long-term complications in glycogen
storage disease IXb (OMIM:261750) patients [44].
Metabolite replacement Hydrocortisone is a replacement therapy for patients with
17-alpha-hydroxylase deficiency (OMIM:202110) [45].
Functional complementation of a genetically defective protein by
stimulation
Sodium valproate activates the expression of one glycogen phosphorylase
isoform, GP-BB, which in turn results in a decrease in intracellular glycogen
accumulation, a dominant feature of glycogen storage disease type V
(OMIM:232600) [46].
Specifically, to ensure interoperability, we followed
the Linked Data principles [48] and linked the entities
described in DDIEM to community reference resources
and ontologies. Diseases are mapped to OnlineMendelian
Inheritance in Man (OMIM) [49] disease identifiers as
well as to identifiers in the IEMbase database [10]. Genes
are linked to the NCBI Entrez gene database [50] and their
products to Expasy [51], KEGG [52], and the UniProt [53]
databases. Wemapped drugs to Drugbank [54], PubChem
[55], ChEBI [56], and to identifiers from the Anatom-
ical Therapeutic Chemical Classification System (ATC).
In DDIEM, we rely on ontologies in the OBO Foundry
[57] as collaboratively developed reference ontologies in
the biomedical domain. We represent phenotypes using
either the Human Phenotype Ontology (HPO) [31] or
the Mammalian Phenotype Ontology (MPO) [32], and we
use the Evidence and Conclusion Ontology (ECO) [47] to
specify different study types and evidences.
DDIEM content is accessible through a website as well
as through a public SPARQL end-point to enable com-
putational access. DDIEM data is also downloadable, and
each release of the data is assigned a unique Digital Object
Identifier (DOI) [59]. To make DDIEM content findable,
we registered DDIEM on the FAIRsharing platform [60]
and the DDIEM ontology in several ontology repositories.
Discussion
There exist several formal data resources for information
on therapies for rare metabolic diseases. However, the
majority of them focus on symptoms, clinical or metabolic
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Fig. 2 Distribution of the therapeutic procedures in DDIEM based on their classes in the DDIEM ontology
aspects rather than therapeutic approaches. For exam-
ple, the Orphanet [14] database includes drugs designated
for treating rare genetic diseases. Similarly, RAMEDIS [9]
focuses on treatments described in case reports for a num-
ber of metabolic diseases. However, neither provide infor-
mation on the mechanism of drug action or on the pheno-
types corrected or alleviated. Another database, IEMbase
[10], provides some therapeutic information but concen-
trates mainly on the clinical and biochemical aspects of
rare metabolic disease, and provides an expert platform
to facilitate their early and accurate diagnosis. To the
best of our knowledge, DDIEM is the first database that
significantly focuses on the treatment to correct or alle-
viate phenotypes associated with the course of a specific
metabolic disease.
However, the main difference between DDIEM and
other databases is its focus on collecting all reports that
provide any evidence for the use of a therapeutic inter-
vention on an IEM, independently of whether the ther-
apy was successful or not. DDIEM therefore provides
information primarily for research use, in particular for
research involving drug repurposing approaches where
Fig. 3 Overview of entity types and their relations in DDIEM. The figure shows the schema of the DDIEM database
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Fig. 4 Distribution of evidence codes used to annotate the supporting evidence for therapeutic procedures included in DDIEM
the negative cases may also provide insights into molec-
ular mechanisms, in particular when used as part of
machine learning approaches.When using DDIEM for the
purpose of drug repurposing, it is important to consider
that the negative cases will likely suffer from reporting
bias [61].
With a focus on phenotypes and mechanisms, DDIEM
uniquely addresses fundamental aspects of rare disease
therapy with the aim of supporting the analysis of the
therapeutic landscape and the development of new treat-
ments. The Data Mining and Repurposing (DMR) task
force of the IRDiRC [62] recently emphasized the impor-
tant contribution of data mining and data integration
to the development of new drugs for rare diseases, and
highlighted the need to get data out of silos – often
semantic silos – to facilitate in silico approaches to drug
development and repurposing. DDIEM is developed on
the FAIR principles to ensure findability, accessibility,
interoperability, and reusability and is accessible either
through a web interface or computationally through the
DDIEMAPI. Use of community standards, databases, and
ontologies permits ready computational integration of
curated DDIEM information into other datasets. DDIEM
therefore provides a dataset that can be reused by a
wide range of researchers, using different methodologi-
cal approaches, to investigate existing and develop new
therapeutic approaches.
The current data in DDIEM does not cover the details
or scale of clinical trials or individual reports, the drug for-
mulation, or the dosage applied. Such information could
further provide valuable information particularly for drug
repurposing. In the future, we plan to expand DDIEM by
adding a limited amount of quantitative information and
dosage, as well as reporting quantitative drug effects.
Conclusion
We developed DDIEM, a database focusing on treat-
ments for Inborn Errors of Metabolism. DDIEM inte-
grates literature-reported treatments for a wide range of
IEMs together with information on the outcome. The
reports range from individual case reports to clinical tri-
als. Consequently, DDIEM provides information on the
on- and off-label uses of drugs and their effects for treat-
ing IEMs andmay be used to accelerate drug development
and drug repurposing for these diseases.
In creating DDIEM we have extensively analyzed pub-
licly available data on the treatment of rare metabolic
diseases, and present it in a way which permits integra-
tion with other datasets and resources. The value we add
to the currently available public data is in our expert
curation and semantic formalization, integrating and pre-
senting this data in a way compliant with FAIR stan-
dards, and making it freely accessible to investigators in
both public and private domains. DDIEM is accessible
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through its website and can be queried computationally.
We support the conclusions and recommendations of the
IRDiRC regarding data integration and exploitation [62],
and believe that DDIEM will contribute to the discovery
or repurposing of drugs for diseases still lacking effective
therapies.
Materials andmethods
Resources used
We rely on literature resources listed in PubMed and
information published on ClinicalTrials.gov to gather
information about treatments that were used for rare
metabolic diseases. For parts of the curation process we
used the GoPubMed software [63] to access and query
literature resources. While PubMed reports on rather
complete studies, ClinicalTrials.gov provides information
for ongoing studies with potential interim results for each
rare disease. We obtained a list of metabolic diseases
from the Genetic and Rare Diseases (GARD) information
center database [64].
Literature curation
To create the DDIEM content, we searched in literature
the disease names or synonyms from the metabolic dis-
ease list we gathered from GARD. In the cases where
we could not find any literature records for the name or
synonyms of a given disease, we used the gene name asso-
ciated with the disease in the search. We then filtered
all the retrieved records by selecting the ones contain-
ing treatment or management information. Since these
diseases are considered rare, we did not exclude any liter-
ature as long as it provides information about therapeutic
interventions, and in which we found explicit evidence for
the correlation between the applied treatment and clin-
ical phenotypes, which are either completely treated or
alleviated. However, in DDIEM, we focused mainly on
pharmacological and, to some extent, on dietary interven-
tions. We then curated the resulting literature documents
manually to extract the metabolic disorder investigated,
the drugs used to treat the disorder, the effects of the treat-
ment, and the suggested mechanism of action. If drugs
exerted their impact differently between patients with the
same metabolic disease due to different genetic variants
in the same gene, we added those variants as an addi-
tional reference. We categorized variants that affect the
effectiveness and success of therapeutic intervention into
two categories based on whether they promoted the drug
effect or not.
We provided all literature references as provenance
information through the DDIEM web interface. After
mappingmost drugs to their identifiers in the cross-linked
databases, there were some therapies we could not link
to any database. Hence, we indicated their identifiers as
non-available (NA).
Additionally, we developed a therapeutic ontology that
describes the mechanism by which the therapeutic proce-
dures act to either adequately treat the disease or modify
disease pathogenesis. We recorded the disease pheno-
types which were treated or improved by the therapeu-
tic procedure and mapped them to reference ontologies.
Similarly, where phenotypes had no matching identifiers
in those ontologies, we referred to identifiers as non-
available (NA).
Data representation and web interface
We represent the content of DDIEM using the Resource
Description Framework (RDF) [65]. First, we normalized
the curated data (which is primarily stored in a comma-
separated values text file format) by mapping the DDIEM
content to their identifiers in different databases (Uniprot,
Expasy, KEGG, OMIM and Drugbank). In the second
step, we represent the DDIEM content using the DDIEM
RDF data model which captures the relations between the
biomedical entitites we characterize in DDIEM.
We developed a web interface to allow users to navi-
gate the DDIEM database. The interface provides a list of
diseases covered in the database along with their details
including treatments, participating drugs, phenotypes,
and references to the publications from which the infor-
mation was extracted. The web interface also provides a
search in the DDIEM resources using disease, drug, and
mode of action of the therapeutic procedure. Further-
more, to enable automated access to the DDIEM content,
we provide a SPARQL endpoint which directly queries the
RDF data we provide.
We further implemented a web server using Node.js
and developed an API for accessing DDIEM resources.
The API response is formatted in either JSON or JSON-
LD format which enables the possibility to build client
applications using the RDF data underlying DDIEM. We
used OpenLink’s Virtuoso database as an RDF store to
store and query the DDIEM data, and all primary data is
stored in the RDF store and the Node.js server retrieves
all data through SPARQL queries. The DDIEM data is also
available for download in RDF format from the DDIEM
website at http://ddiem.phenomebrowser.net.
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